Cyproheptadine and Chlorpromazine Effects on Spasticity
Primary Purpose
Spinal Cord Injuries, Muscle Spasticity
Status
Completed
Phase
Locations
Canada
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Spinal Cord Injuries
Eligibility Criteria
Inclusion Criteria:
Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.
Exclusion Criteria:
- If patients have damage to the nervous system other than to the spinal cord
- Pregnant women
- Elderly Patients and debilitated patients
- Alcoholic Patients
Patients with:
- Known or suspected allergy to the medication or its ingredients
- Cardiovascular disease
- Hypotension
- Coronary artery disease
- Reduced liver or kidney function
- Comatose or depressed states due to CNS depressants
- Blood dyscrasias
- Bone marrow depression
- History of seizures
- Respiratory problems
- Hypocalcemia
- Monoamine oxidase inhibitor therapy
- Angle-closure glaucoma
- Stenosing peptic ulcer
- Symptomatic prostatic hypertrophy
- Bladder neck obstruction
- Pyloroduodenal obstruction
- History of bronchial asthma
- Increased intraocular pressure
- Hyperthyroidism
- Cardiovascular disease
- Hypertension
Patients taking:
- Amphetamines
- Antihistamines-second generation
- Anticonvulsants
- Anticholinergics
- CNS depressants
- Antidepressants
- Hypotensive agents
- Levodopa
- Lithium
Sites / Locations
- University of Alberta
Arms of the Study
Arm 1
Arm 2
Arm Type
Arm Label
Complete Spinal Cord Injured Subjects
Incomplete Spinal Cord Injured Subjects
Arm Description
Patients with no motor scores in their legs and suffering a complete spinal cord injury.
Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
Outcomes
Primary Outcome Measures
Cutaneomuscular Reflex Responses
Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.
Paired motor unit recordings
We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.
Secondary Outcome Measures
Blood pressure and Heart rate
We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.
Full Information
NCT ID
NCT01509885
First Posted
January 10, 2012
Last Updated
November 16, 2012
Sponsor
University of Alberta
1. Study Identification
Unique Protocol Identification Number
NCT01509885
Brief Title
Cyproheptadine and Chlorpromazine Effects on Spasticity
Official Title
Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury
Study Type
Observational
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
4. Oversight
5. Study Description
Brief Summary
The main goal of this research is to understand the neuronal mechanisms that mediate the development of spasticity and motor dysfunction after spinal cord injury. The investigators examine how neurons and neuronal circuits in an injured nervous system adapt to produce the uncontrolled and unwanted muscle contractions that affect the majority (80%) of patients with spinal cord injury. One of the neurons that the investigators study is the motoneuron that excites the muscles of the limbs to produce movement. Previously, the investigators have shown that after spinal cord injury, the excessive and uncontrolled activity of motoneurons during muscle spasms is mediated, in large part, by the activation of calcium currents in the human motoneuron. In human patients the investigators have used recordings from single muscle fibres to estimate the contribution of these calcium currents in activating the motoneuron during muscle spasms. In this proposal, the investigators study why motoneurons recover these calcium currents and self-sustained activity after chronic spinal cord injury. Because the calcium currents require the presence of the monoamine serotonin (5HT) to activate, and this monoamine is greatly reduced after injury, the investigators examine if the calcium currents recover because the 5HT receptors become spontaneously active without the need for 5HT to bind to the receptor, which the investigators hypothesize to be one of the causes of spasticity after spinal cord injury. This research will pave the way to develop new pharmacological and rehabilitative therapies to both control spasticity after spinal cord injury and augment residual motor movements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Muscle Spasticity
7. Study Design
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Complete Spinal Cord Injured Subjects
Arm Description
Patients with no motor scores in their legs and suffering a complete spinal cord injury.
Arm Title
Incomplete Spinal Cord Injured Subjects
Arm Description
Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
Primary Outcome Measure Information:
Title
Cutaneomuscular Reflex Responses
Description
Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.
Time Frame
Change after drug intake at baseline, 30minutes, 60minutes, 90minutes and 120minutes
Title
Paired motor unit recordings
Description
We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.
Time Frame
Change at baseline and 30, 60, 90 and 120min after drug intake
Secondary Outcome Measure Information:
Title
Blood pressure and Heart rate
Description
We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.
Time Frame
Change at baseline and 30, 60, 90, 120 minutes after drug intake
10. Eligibility
Sex
All
Minimum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.
Exclusion Criteria:
If patients have damage to the nervous system other than to the spinal cord
Pregnant women
Elderly Patients and debilitated patients
Alcoholic Patients
Patients with:
Known or suspected allergy to the medication or its ingredients
Cardiovascular disease
Hypotension
Coronary artery disease
Reduced liver or kidney function
Comatose or depressed states due to CNS depressants
Blood dyscrasias
Bone marrow depression
History of seizures
Respiratory problems
Hypocalcemia
Monoamine oxidase inhibitor therapy
Angle-closure glaucoma
Stenosing peptic ulcer
Symptomatic prostatic hypertrophy
Bladder neck obstruction
Pyloroduodenal obstruction
History of bronchial asthma
Increased intraocular pressure
Hyperthyroidism
Cardiovascular disease
Hypertension
Patients taking:
Amphetamines
Antihistamines-second generation
Anticonvulsants
Anticholinergics
CNS depressants
Antidepressants
Hypotensive agents
Levodopa
Lithium
Study Population Description
Spinal Cord Injury Patients
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Monica A Gorassini, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2R3
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
20512126
Citation
Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R, Heckman CJ, Mashimo T, Vavrek R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med. 2010 Jun;16(6):694-700. doi: 10.1038/nm.2160. Epub 2010 May 30.
Results Reference
result
Links:
URL
http://www.scialberta.ca/
Description
Related Info
Learn more about this trial
Cyproheptadine and Chlorpromazine Effects on Spasticity
We'll reach out to this number within 24 hrs